Embecta Corp Stock Price, News & Analysis

Embecta (NASDAQ:EMBC) reported strong Q3 fiscal 2025 results with revenues of $295.5 million, up 8.4% year-over-year. The company achieved notable growth in both U.S. (11.6%) and International (5.0%) markets. Key financial metrics include adjusted operating income of $109.1 million with a 36.9% margin, and adjusted earnings per share of $1.12, up from $0.74 in the prior year.

The company completed several strategic initiatives, including implementing their ERP system and operationalizing distribution centers in India. Embecta also made progress in co-packaging agreements for GLP-1 drugs and reduced debt by $52.4 million during Q3, bringing year-to-date debt reduction to $112 million. The company declared a quarterly dividend of $0.15 per share and raised its fiscal 2025 guidance.

Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for its common stock. The dividend will be paid on September 15, 2025, to shareholders of record as of the close of business on August 29, 2025.

Embecta (Nasdaq: EMBC), a medical supplies company specializing in insulin delivery, has scheduled its fiscal third quarter 2025 financial results conference call for August 8, 2025, at 8:00 a.m. ET. The company will present financial results, provide operational updates, and host a Q&A session.

Investors can access the presentation through a live webcast or teleconference. A replay will be available from 11:00 a.m. ET on the same day through the company's investor relations website, where it will remain archived for one year.

Embecta (NASDAQ: EMBC), a medical supplies company specializing in insulin delivery, has announced its participation in four major investor conferences in May and June 2025:

• Goldman Sachs Leveraged Finance Conference (May 29) - One-on-one meetings in Dana Point, CA
• Jefferies Global Healthcare Conference (June 5) - Fireside session at 4:55 PM EDT in NYC
• Goldman Sachs Global Healthcare Conference (June 10) - Fireside session at 1:20 PM EDT in Miami
• Truist Securities MedTech Conference (June 17) - One-on-one meetings in Boston

Embecta Corp. (NASDAQ: EMBC) reported its Q2 FY2025 financial results with revenues of $259.0 million, down 9.8% from the previous year. The company saw a decrease in both U.S. revenues (-8.4%) and international revenues (-11.3%). Despite revenue challenges, profitability metrics improved with adjusted operating income margin increasing to 31.4% from 26.1% and adjusted EBITDA margin rising to 37.5% from 31.6%. Adjusted earnings per share reached $0.70, up from $0.67. The company announced a quarterly dividend of $0.15 per share and reduced debt by paying down approximately $27.4 million. For FY2025, Embecta updated its guidance, projecting revenues between $1,073-$1,090 million and maintaining adjusted EPS guidance of $2.70-$2.90 despite lowered revenue expectations.

Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for all outstanding common stock. The dividend will be paid on June 13, 2025 to stockholders who are on record as of the close of business on May 28, 2025.

Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced its upcoming Analyst and Investor Day scheduled for May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.

The event will feature presentations from President & CEO Dev Kurdikar, CFO Jake Elguicze, and other leadership team members. They will discuss:

• Strategic and business overview
• Value creation opportunities
• Company's financial profile
• Long-term objectives

While in-person attendance is by invitation only, interested parties can participate via webcast through InvestorDay.embecta.com. A replay and presentation materials will be available in the 'Events & Presentations' section of the company's Investor Relations website after the event.

Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced it will host a conference call to discuss its fiscal second quarter 2025 financial results on Friday, May 9, 2025, at 8:00 a.m. Eastern Time.

The company will provide an operational update and conduct a question and answer session during the call. Interested parties can access the live webcast through the company's investor relations website at investors.embecta.com. A replay of the webcast will be available from 11:00 a.m. ET on the same day and will remain archived on the website for one year.

Embecta (EMBC) announced the publication of new global insulin injection recommendations in the Mayo Clinic Proceedings, marking the first major update in nearly 10 years. The FITTER Forward Expert Recommendations, authored by 16 diabetes specialists from 13 countries, aims to enhance clinical outcomes for diabetes patients worldwide through improved insulin injection techniques.

The recommendations focus on several key areas including: new insights on injection device technology, standardized injection techniques to prevent complications, structured training programs for healthcare providers, and patient-centered recommendations to improve therapy adherence. Led by Dr. David Klonoff, the initiative emphasizes the critical importance of proper insulin administration techniques in maintaining target blood glucose levels.

Embecta will host a webinar on April 8, 2025, at 12 pm EST featuring FITTER Forward authors to discuss the new recommendations and their clinical impact.